Na Li

Na Li

Auto-generated profile, based on publicly available information

Na Li

Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2017 in International Journal of Stroke
Verified
Journal Article
Closed access
LLLiping Liu
Liping Liu
YWYilong Wang
Yilong Wang
XMXia Meng
Xia Meng
NLNa Li
Na Li
YTYing Tan
Ying Tan
XZXingquan Zhao
Xingquan Zhao
Rationale: Acute intracerebral hemorrhage inflicts a high-economic and -health burden. Computed tomography angiography spot sign is a predictor of hematoma expansion, is associated with poor clinical outcome and is an important stratifying variable for patients treated with haemostatic therapy. Aims: We aim to compare the effect of treatment with tranexamic acid to placebo for the prevention of hemorrhage growth in patients with high-risk acute intracerebral hemorrhage with a positive spot sign. Design: The tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign (TRAIGE) is a prospective, multicenter, placebo-controlled, double-blind, investigator-led, randomized clinical trial that will include an estimated 240 participants. Patients with intracerebral hemorrhage demonstrating symptom onset within 8 h and with the spot sign as a biomarker for ongoing hemorrhage, and no contraindications for antifibrinolytic therapy, will be enrolled to receive either tranexamic acid or placebo. The primary outcome measure is the presence of hemorrhage growth defined as an increase in intracerebral hemorrhage volume >33% or >6 ml from baseline to 24 ± 2 h. The secondary outcomes include safety and clinical outcomes. Conclusion: The TRAIGE trial evaluates the efficacy of haemostatic therapy with tranexamic acid in the prevention of hemorrhage growth among high-risk patients with acute intracerebral hemorrhage.

1 April 2018 in Experimental Eye Research
Verified
Journal Article
Closed access
YTYufei Teng
Yufei Teng
GYGary Yam
Gary Yam
NLNa Li
Na Li
SWShen Wu
Shen Wu
AGArkasubhra Ghosh
Arkasubhra Ghosh
Vishal JhanjiVishal Jhanji
Vishal Jhanji

1 June 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
GZGuoying Zhang
Guoying Zhang
NLNa Li
Na Li
YTYongjuan Tong
Yongjuan Tong
PLPeilin Li
Peilin Li
HHHaotian Han
Haotian Han
LCLei Cui
Lei Cui

26 August 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
NLNa Li
Na Li
LCLei Cui
Lei Cui
HMHonghao Ma
Honghao Ma
ZGZhihua Gong
Zhihua Gong
HLHongyun Lian
Hongyun Lian
TWTianyou Wang
Tianyou Wang

24 July 2021 in Pituitary
Verified
Journal Article
Closed access
PDF file
HLHongyun Lian
Hongyun Lian
LCLei Cui
Lei Cui
YYYing Yang
Ying Yang
AWAng Wei
Ang Wei
Hua ChengHua Cheng
Hua Cheng
RZRui Zhang
Rui Zhang

1 April 2026 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
NLNa Li
Na Li
YYYing Yang
Ying Yang
ZGZhihua Gong
Zhihua Gong
HLHongyun Lian
Hongyun Lian
HMHonghao Ma
Honghao Ma
RZRui Zhang
Rui Zhang
Background: A portion of children with Langerhans cell histiocytosis (LCH) exhibit recurrent or persistent disease-related fever at their first visit. We aimed to clarify the clinical characteristics, laboratory indicators, prognostic differences, and optimal regimens for these children with fever. Methods: A cross-sectional design (single-center, retrospective, and observational) was adopted for this study. A total of 448 pediatric patients diagnosed with LCH in our hospital from January 2016 to December 2019 were retrospectively enrolled and divided into two groups: children with fever (n=52) and children without fever (n=396). The clinical characteristics, laboratory indicators, and outcomes of regimens for these children were analyzed with SPSS 16.0 software. Results: Children with initial fever had distinct clinical characteristics and laboratory indicators, including an age younger than two years, risk-organ involvement, accompanying hemophagocytic syndrome, and higher levels of cell-free DNA BRAFV600E mutation, among others. Patients in the fever group also had a significantly lower treatment efficacy from first-line treatment and a lower 3-year progression-free survival (PFS) rate (approximately 5.22% and 64.23%, respectively; P<0.001). Multivariate Cox regression analysis indicated that fever, risk-organ involvement, skin involvement, ferritin level, and dynamic erythrocyte sedimentation rate were independently prognostic factors for outcomes of first-line treatment. However, the 3-year PFS rates did not differ significantly between patients with fever and without fever after the administration of second-line or target regimens. Conclusions: Among pediatric patients with LCH, those with initial fever exhibit more severe clinical symptoms and worse prognoses after first-line chemotherapy. Alternative strategies may mitigate fever-associated risk, and this possibility should be confirmed through prospective research.